



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

4 August 2017
EMA/506776/2017
Information Management Division

Applications for new human medicines under evaluation by the Committee for Medicinal Products for Human Use August 2017

This document lists information on applications for centralised marketing authorisation for human medicines that the European Medicines Agency has received for evaluation. It includes the international non-proprietary names (INN) and therapeutic areas for all new innovative medicines under evaluation by the Committee for Medicinal Products for Human Use (CHMP). For generic and biosimilar medicines, it includes the INN (active moiety only, with no information on salt, ester or derivative) and therapeutic area.

This list only includes information for medicines whose applications have been validated at the time the report was compiled. The information in this report was compiled on **4 August 2017**.

Information on designated orphan medicines that are being assessed for marketing authorisation is also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

Information in **bold** corresponds to new entries in the monthly list.

Entries are removed from this list once the medicine has received a positive or negative opinion from the CHMP or when the applicant has withdrawn the application. The Agency publishes information on these opinions and withdrawn applications on its website.

Information on CHMP opinions is also published in the monthly CHMP highlights.



Non-orphan medicinal products

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Abaloparatide	Calcium homeostasis
Andexanet alfa	Other therapeutic medicines
Benralizumab	Medicines for obstructive airway diseases
Betrixaban	Antithrombotic medicines
Bictegravir / emtricitabine / tenofovir alafenamide (fumarate)	Antivirals for systemic use
Binimetinib	Antineoplastic medicines
Botulinum toxin type A	Muscle relaxants
Brexpirazole	Psycholeptics
Brigatinib	Antineoplastic medicines
Ciclosporin	Ophthalmologicals
D-biotin	Vitamins
Dengue tetravalent vaccine (live, attenuated)	Vaccines
Dolutegravir (sodium) /rilpivirine (hydrochloride)	Antivirals for systemic use
Emicizumab ⁱⁱ	Antihemorrhagics
Enclomifene (citrate)	Sex hormones and modulators of the genital system
Erenumab	Analgesics
Ertugliflozin (L-pyroglutamic acid)	Medicines used in diabetes
Ertugliflozin (L-pyroglutamic acid) / metformin (hydrochloride)	Medicines used in diabetes
Ertugliflozin (L-pyroglutamic acid) / sitagliptin (phosphate monohydrate)	Medicines used in diabetes
Fluticasone furoate / umeclidinium (bromide) / vilanterol (trifenatate)	Medicines for obstructive airway diseases
Glycopyrronium / formoterol (fumarate dihydrate)	Medicines for obstructive airway diseases
Guselkumab	Immunosuppressants
Human fibrinogen / human thrombin	Antihemorrhagics
Human herpesvirus 3	Vaccines
Lesinurad / allopurinol	Antigout medicines
Melatonin	Psycholeptics
Meropenem / vaborbactam	Antibacterials for systemic use
Naldemedine (tosilate)	Medicines for constipation

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Neratinib	Antineoplastic medicines
Ocrelizumab	Immunosuppressants
Padeliporfin (di-potassium)	Antineoplastic medicines
Peramivir	Antivirals for systemic use
Prasterone	Sex hormones and modulators of the genital system
Rurioctocog alfa pegol	Antihemorrhagics
Semaglutide	Medicines used in diabetes
Sirukumab	Immunosuppressants
Tildrakizumab	Immunosuppressants

ⁱ Based on the ATC therapeutic sub-group.

ⁱⁱ Application being reviewed under EMA's accelerated assessment programme.

Non-orphan generic and biosimilar medicinal products

International non-proprietary name / Common Name	Therapeutic area ⁱ	Total number of applications
Adalimumab	Immunosuppressants	3
Anagrelide	Antineoplastic medicines	1
Bevacizumab	Antineoplastic medicines	2
Buprenorphine / naloxone	Other nervous system medicines	1
Carmustine	Antineoplastic medicines	1
Darunavir	Antivirals for systemic use	2
Deferiprone	Other therapeutic medicines	1
Doxorubicin	Antineoplastic medicines	1
Efavirenz / emtricitabine / tenofovir disoproxil	Antivirals for systemic use	1
Fulvestrant	Endocrine therapy	1
Hydrocortisone	Corticosteroids for systemic use	1
Imatinib	Antineoplastic medicines	1
Infliximab	Immunosuppressants	1
Insulin glargine	Medicines used in diabetes	1
Miglustat	Other alimentary tract and metabolism products	1

International non-proprietary name / Common Name	Therapeutic area ⁱ	Total number of applications
Naloxone	Other therapeutic medicines	1
Nitisinone	Other alimentary tract and metabolism products	1
Pegfilgrastim	Immunostimulants	3
Pemetrexed	Antineoplastic medicines	1
Prasugrel	Antithrombotic medicines	1
Ritonavir	Antivirals for systemic use	1
Rotigotine	Anti-parkinson medicines	1
Sufentanil	Anesthetics	1
Tacrolimus	Immunosuppressants	1
Trastuzumab	Antineoplastic medicines	5

ⁱ Based on the ATC therapeutic sub-group.

Orphan medicinal products

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Budesonide ⁱⁱ	Antidiarrheals, intestinal antiinflammatory/antiinfective medicines
Burosumab	Medicines for bone diseases
Caplacizumab	Antithrombotic medicines
Eteplirsen	Other medicines for disorders of the musculo-skeletal system
Expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue	Immunosuppressants
Gemtuzumab ozogamicin	Antineoplastic medicines
Glibenclamide ⁱⁱ	Medicines used in diabetes
Letermovir ⁱⁱ	Antivirals for systemic use
Masitinib (mesylate)	Antineoplastic medicines
Metreleptin	Other alimentary tract and metabolism products
Niraparib (tosylate monohydrate)	Antineoplastic medicines
Paclitaxel	Antineoplastic medicines
Pacritinib (citrate)	Antineoplastic medicines

International non-proprietary name (salt, ester, derivative, etc.) / Common Name	Therapeutic area ⁱ
Plitidepsin	Antineoplastic medicines
Ropeginterferon alfa-2b	Immunostimulants
Rucaparib (camsylate)	Antineoplastic medicines
Sodium benzoate	Other alimentary tract and metabolism products
Velmanase alfa	Other alimentary tract and metabolism products
Vestronidase alfa	Other alimentary tract and metabolism products
Viable T-cells	Antineoplastic and immunomodulating agents
Vonicog alfa	Antihemorrhagics

ⁱ Based on the ATC therapeutic sub-group.

ⁱⁱ Application being reviewed under EMA's accelerated assessment programme.